Posters

Evaluation of ocular complications and their related factors in patients with thalassemia major treated with Deferoxamine

Poster Details

First Author: M.Davari IRAN

Co Author(s):    M. Reznani   R. Rezvani                 

Abstract Details

Purpose:

Thalassemia is a genetic disorder in the globulin chain. There are two main forms of thalassemia thalassemia major is more serious and is associated with many problems. deferoxamine, are used to treat and prevent this condition. Heredity of the disease and its onset in the first years of life, the likelihood of physical malformations, the constant need for blood transfusions and the use of Desferal that have important effects on the development of children ,so the aim of this study was to evaluate the ocular complications associated with deferoxamine in major thalassemia patients treated with deferoxamine.

Setting:

Ophthalmology Dept. Cardiovascular Disease Research Center, Birjand University of Medical Sciences, Birjand, Iran. This descriptive study was performed on 57 patients with thalassemia major in South Khorasan

Methods:

Inclusion criteria include thalassemia major based on electrophoresis in patient records, drug treatment with Desferal and their consent to participate in the study. Patients with diabetes and with hereditary ocular disorders were excluded because of the inability to differentiate between the ocular complications caused by thalassemia and the complications of diabetes. The selected individuals were examined by an ophthalmologist and each patient was individually assessed for health and ocular conditions, probable factors associated with the prevalence of ocular complications and problems, including sex factors, dose and duration of treatment, and Serum ferritin level. Results were analyzed by SPSS 16 software.

Results:

This study was performed on 57 patients with thalassemia including 33 males (57.9%) and 24 females (42.1%) with mean age of 14.97 6 6.27. Night blindness and ophthalmic disorders were seen in one patient and refractive error in 31.6% of patients. There was no significant difference between the sexes and night blindness, refractive errors and ophthalmic disorders. (P> 0.05). There was a significant difference between the mean duration of Desferal administration and the presence or absence of ophthalmic disorders (P <0.05). There was no significant difference between mean duration of Desferal administration and serum ferritin level and presence or absence of refractive error (P> 0.05).

Conclusions:

Early treatment with thalassemia patients reduces the risk of ocular diseases

Financial Disclosure:

None